{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "2019 novel coronavirus disease",
      "Australia",
      "COVID-19",
      "Omicron",
      "SARS-CoV-2",
      "SARS-CoV-2\u2013naive",
      "coronavirus disease",
      "respiratory infections",
      "severe acute respiratory syndrome coronavirus 2",
      "vaccine effectiveness",
      "viruses",
      "zoonoses"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37141626",
  "DateCompleted": {
    "Year": "2023",
    "Month": "05",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "06",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "05",
        "Day": "04"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.3201/eid2906.230130"
    ],
    "Journal": {
      "ISSN": "1080-6059",
      "JournalIssue": {
        "Volume": "29",
        "Issue": "6",
        "PubDate": {
          "Year": "2023",
          "Month": "Jun"
        }
      },
      "Title": "Emerging infectious diseases",
      "ISOAbbreviation": "Emerg Infect Dis"
    },
    "ArticleTitle": "SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022.",
    "Pagination": {
      "StartPage": "1162",
      "EndPage": "1172",
      "MedlinePgn": "1162-1172"
    },
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 transmission in Western Australia, Australia, was negligible until a wave of Omicron variant infections emerged in February 2022, when >90% of adults had been vaccinated. This unique pandemic enabled assessment of SARS-CoV-2 vaccine effectiveness (VE) without potential interference from background immunity from prior infection. We matched 188,950 persons who had a positive PCR test result during February-May 2022 to negative controls by age, week of test, and other possible confounders. Overall, 3-dose VE was 42.0% against infection and 81.7% against hospitalization or death. A primary series of 2 viral-vectored vaccines followed by an mRNA booster provided significantly longer protection against infection >60 days after vaccination than a 3-dose series of mRNA vaccine. In a population free from non-vaccine-derived background immunity, vaccines against the ancestral spike protein were \u224880% effective for preventing serious outcomes from infection with the SARS-CoV-2 Omicron variant."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bloomfield",
        "ForeName": "Lauren E",
        "Initials": "LE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ngeh",
        "ForeName": "Sera",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cadby",
        "ForeName": "Gemma",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hutcheon",
        "ForeName": "Kate",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Effler",
        "ForeName": "Paul V",
        "Initials": "PV"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Emerg Infect Dis",
    "NlmUniqueID": "9508155",
    "ISSNLinking": "1080-6040"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Viral Vaccines"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccine Efficacy"
    },
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Australia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Viral Vaccines"
    }
  ]
}